Mood Stabilizers for Bipolar Disorder: How They Work, What to Expect, and How to Choose

You’ve probably heard the word “mood stabilizer” more times than you can count — from prescribers, discharge paperwork, maybe a pharmacist who handed you a dense printout and moved on to the next window. What you may not have heard is a clear explanation of how these medications actually differ from each other, why a specialist might choose one over another, and what it means for your specific pattern of episodes.

That’s what this article is for. Whether you’re newly diagnosed, questioning whether your current medication is doing enough, or trying to understand what options exist beyond what you’ve already tried, this is a detailed, evidence-based guide to the four main mood stabilizers for bipolar disorder — how they work, what the research shows, and what the clinical decision logic actually looks like.

If you want to understand what bipolar-specialized medication management looks like in practice, get started with Sway Health — a telehealth clinic built specifically around bipolar disorder.

The Stakes: Why Getting the Right Mood Stabilizer Actually Matters

Bipolar disorder is not a minor inconvenience to be managed on the margins. A 2023 review in JAMA found that people with bipolar disorder spend approximately 75% of their symptomatic time in depressive episodes or mixed states — not mania. The same review noted that the annual suicide rate in bipolar disorder is approximately 0.9% per year versus 0.014% in the general population — roughly 64 times higher, and that more than 50% of patients are not adherent to treatment at any given time.

That non-adherence figure isn’t a character flaw. It’s often a signal that the treatment isn’t working well enough to justify its cost in side effects, monitoring burden, or disruption to daily life. And when care is generic — designed for the average psychiatric patient rather than for someone with bipolar specifically — that gap between what medication could do and what it’s actually doing tends to widen.

The four mood stabilizers discussed in this article — lithium, valproate/divalproex, lamotrigine, and carbamazepine — have distinct mechanisms, distinct strengths by illness phase, and distinct side effect and monitoring profiles. Understanding those differences is the first step toward being able to advocate for care that fits you.

According to the Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 guidelines, bipolar disorder affects more than 2% of the global population and is among the most complex psychiatric conditions to treat — precisely because its phases require different pharmacological approaches. To explore your broader bipolar treatment options, including therapy and integrated care models, the CANMAT framework is a useful reference point.

Key Takeaway: Bipolar disorder is a depression-dominant illness. Choosing the right mood stabilizer — one matched to your predominant polarity and episode pattern — has direct consequences for how much of your life you spend symptomatic.

What Mood Stabilizers Actually Are (And What They’re Not)

Mood stabilizer is a functional label, not a pharmacological class. It describes medications used to reduce the frequency and severity of mood episodes in bipolar disorder — covering mania, hypomania, depression, and mixed states, either acutely or as long-term prevention (maintenance).

The American Psychiatric Association (APA) identifies mood stabilizers as the most commonly prescribed medication type for bipolar disorder. The category includes lithium (an alkali metal ion), anticonvulsants (originally developed for epilepsy), and atypical antipsychotics. This article focuses on the four traditional mood stabilizers most commonly used in bipolar care: lithium, valproate/divalproex, lamotrigine, and carbamazepine.

One thing worth naming clearly: mood stabilizers are not antidepressants, and they are not interchangeable with them. The NIMH notes that antidepressants are not used alone in bipolar disorder because they can trigger manic episodes or rapid cycling. If antidepressants are part of your current regimen and you have questions about that, Sway has a detailed guide on the risks of antidepressants in bipolar disorder worth reading alongside this one.

How Mood Stabilizers Work: A Plain-Language Breakdown

Each of the four main mood stabilizers works through a different mechanism:

Lithium operates partly through what’s known as the inositol depletion hypothesis — it inhibits inositol monophosphatase, which reduces excessive neuronal excitation in overactive brain circuits. It also inhibits GSK-3β, a kinase involved in neuronal survival and plasticity. In plain terms: research suggests lithium calms circuits that are firing too hard, while also having neuroprotective effects not seen with other mood stabilizers.

Valproate/Divalproex works primarily by enhancing the inhibitory effects of GABA (gamma-aminobutyric acid) — the brain’s primary “brake” neurotransmitter — and by reducing repetitive neuronal firing. This mechanism translates into fast, robust antimanic effects.

Lamotrigine selectively blocks voltage-gated sodium channels, which stabilizes the presynaptic neuronal membrane and reduces the release of excitatory neurotransmitters like glutamate and aspartate. This glutamate-quieting effect is thought to underlie its particular strength in preventing depressive episodes.

Carbamazepine works through multiple pathways — including inhibiting cAMP accumulation and downregulating the inositol transporter — producing broad stabilizing effects. It has strong evidence for acute mania but more limited depression data.

Key Takeaway: The mechanism differences matter. Lamotrigine’s glutamate-quieting profile explains why it’s stronger for depression; valproate’s GABA-boosting profile explains why it’s faster for mania. Mechanism informs clinical choice.

The Head-to-Head Comparison: Lithium, Valproate, Lamotrigine, and Carbamazepine

This is the table competitors don’t offer. Below is a structured comparison across the evidence dimensions that matter most for real clinical decision-making. Sources are cited inline throughout this section.

CANMAT line designations from Yatham et al. 2018 CANMAT/ISBD (International Society for Bipolar Disorders) guidelines and Keramatian et al. 2023 CANMAT update. Mechanisms from StatPearls/NCBI 2023. Phase efficacy from Fountoulakis et al. 2022, Haenen et al. 2024, Hashimoto et al. 2021 Cochrane review, Grunze et al. 2021. Safety from Nguyen et al. 2009, Duce et al. 2023, Gomes-da-Costa et al. 2022.

Key Takeaway: No single mood stabilizer wins across all dimensions. The clinical task is matching the drug’s evidence profile to your illness profile — polarity pattern, phase history, tolerability priorities, and life circumstances.

A Closer Look at Each Medication

Lithium: The Gold Standard — With Caveats Worth Knowing

Lithium has been used in bipolar disorder since the 1940s and remains, for many people, the closest thing to a gold standard the field has. A 2024 analysis of 59 clinical studies found that lithium was superior to aripiprazole, valproic acid, and quetiapine in reducing manic symptoms, and produced a lower relapse rate than valproate.

But lithium’s most clinically significant property may be its effect on suicide risk. A 2024 meta-analysis of 13 randomized controlled trials found that long-term lithium treatment was associated with an odds ratio of 0.491 for suicidal acts versus comparators — meaning it roughly halved the risk. The NIMH is explicit: “Lithium also can decrease the risk of suicide.” No other mood stabilizer carries this level of evidence for suicide prevention.

One concern that often surfaces in conversations about lithium is weight gain. A 2022 systematic review and meta-analysis of 20 studies found that the average weight increase with lithium was 0.462 kg — not statistically significant (p=0.158), and actually lower than with active comparators like other mood stabilizers and antipsychotics. This is worth knowing if weight has been a reason to hesitate.

The tradeoff is monitoring. Lithium has a narrow therapeutic window, and levels outside the target range can cause toxicity or lose efficacy. A 2023 real-world study confirmed that 6-monthly thyroid function testing is standard of care — and that approximately 91% of thyroid dysfunction in lithium patients manifests within the first three years of treatment. Regular creatinine and renal function tests are also standard, as chronic lithium use can affect kidney function in a subset of patients.

Lamotrigine: The Depression Specialist

If lithium is the gold standard for mania-dominant bipolar, lamotrigine occupies an equally important niche for people whose illness is dominated by depression. A 2024 meta-analysis found that lamotrigine as an add-on during acute depressive episodes produced significantly greater decreases in depressive symptoms versus placebo (SMD — standardized mean difference — −0.30, p=0.004), and that maintenance lamotrigine was associated with a significantly lower relapse or recurrence rate than placebo (RR 0.84).

A key nuance, though: research from a 2009 individual patient data meta-analysis found that lamotrigine’s antidepressant benefit is concentrated in people with severe bipolar depression (HRSD — the Hamilton Rating Scale for Depression — score >24). In people with mild-to-moderate depression, the benefit versus placebo was not statistically significant. This means lamotrigine may be most appropriate when depression is the heaviest part of the illness burden.

What lamotrigine does not do well is mania. The 2021 Cochrane systematic review found that manic recurrence was significantly higher with lamotrigine than lithium (RR 2.13, 95% CI 1.32–3.44). For someone with frequent manic episodes, lamotrigine alone is not a sufficient safety net.

The titration protocol for lamotrigine is slow by design. CAMH guidelines recommend starting at a very low dose and increasing over four weeks or more — because rushing the titration is associated with a higher risk of rash, including the rare but serious Stevens-Johnson syndrome (SJS). If you’re also taking valproate, your prescriber will need to adjust the lamotrigine dose, because valproate roughly doubles lamotrigine blood levels.

Lamotrigine also requires no routine blood level monitoring — a real quality-of-life advantage for many people.

For a deeper look at medication options specifically for the depressive phase of bipolar disorder, Sway’s guide to medication for bipolar depression covers lamotrigine’s role alongside other evidence-based approaches.

Valproate/Divalproex: Fast, Effective for Mania — With Important Limits

Valproate (sold as Depakote or Depakene; the extended-release formulation is divalproex) is among the most widely prescribed mood stabilizers in the United States. Its antimanic efficacy is well-established: a peer-reviewed review notes that its effectiveness for acute mania has been demonstrated in randomized controlled trials versus placebo, lithium, haloperidol, and olanzapine.

One clinical advantage of valproate is the option for rapid loading — getting to therapeutic levels quickly when mania needs to be controlled fast. This makes it a common choice in inpatient or acute settings.

Where valproate underperforms is in bipolar depression. The evidence base for its antidepressant effects in bipolar disorder is thin compared to its mania evidence — which matters enormously given that approximately 75% of symptomatic time in bipolar disorder is depressive in nature.

The pregnancy risk with valproate is the most serious concern in this drug class. A 2009 review of teratogenicity across mood stabilizers found that valproate carries a 6.2%–16% rate of major congenital malformations and a 1%–5% risk of neural tube defects. In-utero exposure is also associated with decreased verbal IQ and higher rates of developmental difficulty. For anyone who may become pregnant, this risk profile is one of the most important factors in medication selection.

Carbamazepine: A Niche Role, Not a First Call

Carbamazepine (brand names Tegretol, Equetro) has genuine antimanic efficacy — a 2021 review of 84 studies found that it meets Class A criteria for acute mania and prevention of manic relapses — but its place in bipolar treatment has narrowed significantly due to its side effect profile and its extensive CYP450 enzyme-inducing activity.

CYP450 induction means carbamazepine accelerates the metabolism of dozens of other drugs — including hormonal contraceptives, anticoagulants, and other psychotropic medications. Managing these interactions requires careful coordination. CAMH specifically flags its use as most appropriate for mania and mixed states that have not responded to lithium — or for people with irritability and agitation as prominent features.

Carbamazepine is generally a second- or third-line option per CANMAT guidelines, reached after first-line medications have been tried or are not tolerated.

Key Takeaway: Valproate and lithium are strong for mania; lamotrigine is the best-evidenced option for depression prevention. Carbamazepine fills a niche for treatment-resistant cases. Understanding this polarity split is core to understanding why medication changes happen.

How a Bipolar Specialist Actually Chooses

This is the section most articles don’t include. Prescribing is not a flowchart — it’s a synthesis of clinical factors that are unique to each person. That said, the reasoning follows recognizable logic.

If you want to understand what thoughtful, evidence-aligned bipolar prescribing looks like, explore bipolar treatment at Sway Health — a practice built around this kind of specialist decision-making.

Polarity Pattern: Mania-Dominant vs. Depression-Dominant

The first question a bipolar specialist considers is which pole dominates your history. If manic and hypomanic episodes have caused the most disruption — job losses, hospitalization, relationship damage during elevated states — the priority is a medication with strong antimanic and maintenance properties. The CANMAT 2018/2023 guidelines designate lithium and valproate as first-line for acute mania.

If depressive episodes have been the heavier burden — and for many people with bipolar they are — the calculus shifts toward lamotrigine for maintenance, often in combination with another agent.

Suicidality: Where Lithium Has Unique Standing

If suicidality has been part of your episode history, lithium’s anti-suicide evidence is clinically significant enough that many specialists consider it the preferred option — all else being equal. A 2024 meta-analysis covering 13 randomized controlled trials found lithium reduced the odds of suicidal acts by approximately half compared to all other comparators, including carbamazepine, lamotrigine, olanzapine, quetiapine, and valproate. This evidence profile is unique to lithium — no other mood stabilizer carries comparable data.

Tolerability and Monitoring Burden

For some people, the prospect of regular blood draws — lithium levels, renal panels, thyroid tests — is genuinely burdensome. That’s a legitimate factor, not a compliance problem. Lamotrigine’s absence of required blood monitoring is a real quality-of-life advantage. A Cochrane review confirmed that adverse effects at 6–12 months were significantly lower with lamotrigine than lithium.

For others, the structured monitoring that comes with lithium feels like a safety net — regular contact with the care system, objective data about what their body is doing.

Reproductive Considerations

For people who may become pregnant, the teratogenicity hierarchy is: valproate (highest risk, generally avoided in reproductive-age patients) > carbamazepine > lamotrigine > lithium. This doesn’t mean these medications cannot be used during pregnancy — it means the decision requires careful, individualized discussion weighing the risk of untreated bipolar episodes against medication exposure.

Precision Medicine: Who Responds Best to Lithium?

Not everyone responds equally to lithium, and researchers have identified some predictors of stronger response. A 2024 review of lithium’s clinical evidence notes that family history of bipolar disorder, a classic episodic pattern (full remission between episodes), and a mania-first episode sequence tend to be associated with better lithium outcomes. Pharmacogenomics — the study of how genetic variation affects drug metabolism — is also an emerging area, with certain genetic markers linked to lithium response rates.

This is why a thorough psychiatric history, not just a symptom snapshot, matters in bipolar prescribing.

Key Takeaway: The “best” mood stabilizer is the one that fits your polarity pattern, your history with suicidality, your reproductive plans, your tolerance for monitoring, and your response pattern. That’s a specialized clinical conversation — not a one-size-fits-all decision.

What to Expect When Starting a Mood Stabilizer

Timeline: This Is Not Immediate

CAMH is clear that mood stabilizers can take up to several weeks to reach their full effect. This is one of the most important things to understand early — the first two to four weeks are not an accurate window into how the medication will perform at steady state.

Lamotrigine’s slow titration means it may take 8–12 weeks before you’re at a therapeutic dose. Lithium requires serum level checks to ensure you’re within the therapeutic range. These timelines require patience that can be genuinely difficult during a depressive phase.

Monitoring: Empowerment, Not Just Burden

The monitoring requirements for lithium and valproate — blood draws, level checks, thyroid and kidney panels — are often framed as inconveniences. A different framing: they are the feedback mechanism that makes precision prescribing possible.

Knowing your lithium level tells you and your prescriber whether you’re in the range where efficacy has been demonstrated. Research confirms that thyroid dysfunction from lithium develops primarily within the first three years, and that 6-monthly testing reliably catches it early — before it becomes symptomatic. Renal monitoring tracks whether the kidneys are being affected and allows dose adjustments before problems escalate.

Tracking your symptoms between appointments is equally important. Sway’s Baseline mood tracking app is designed specifically for this purpose — helping you bring real data into the clinical conversation, rather than trying to reconstruct three months of mood history in a 20-minute appointment.

Drug Interactions to Know

Carbamazepine’s enzyme-inducing activity is the most extensive interaction risk. Valproate and lamotrigine have a specific and important interaction: valproate inhibits lamotrigine’s metabolism, roughly doubling lamotrigine blood levels — which means if you’re starting or stopping valproate while on lamotrigine (or vice versa), dose adjustments are required. StatPearls’ clinical reference covers this interaction in detail. NSAIDs and diuretics can raise lithium levels to potentially toxic ranges — something to watch for during illness, travel, or hot weather that causes dehydration.

Stopping Medication: What the Evidence Says

CAMH’s guidance is direct on this: stopping mood stabilizers greatly increases the chances of another episode. The APA notes that because bipolar disorder is a chronic illness in which episodes typically recur, ongoing preventive treatment is generally recommended. This is a conversation to have with your prescriber — not a decision to make independently.

Key Takeaway: Starting a mood stabilizer involves a realistic timeline, structured monitoring, and awareness of drug interactions. Knowing what to expect — and why each step matters — makes it possible to stay engaged with the process even when it’s slow.

When Your Current Medication Feels Like It’s Plateaued

This section is for people already in care who feel like their medication is doing something — just not enough.

If you’ve been stable on lithium or lamotrigine for a year and depression keeps breaking through, that’s clinically meaningful information. It may suggest that the depression-prevention arm of your regimen needs strengthening — for example, adding or titrating lamotrigine if lithium is carrying the mania burden, or considering augmentation with a medication with specific bipolar depression evidence.

If mania or hypomania remains a recurring problem despite your current regimen, it may point to insufficient serum levels, a medication that isn’t well-matched to your polarity, or a need for combination therapy. A 2024 analysis found that 14 of 22 add-on therapies to lithium showed predominantly positive effects versus lithium monotherapy — suggesting that augmentation, rather than replacement, is often the right clinical direction.

The “plateau” conversation is one that requires a prescriber who knows bipolar specifically — not just general psychiatry. Someone who can look at your episode history, your current serum levels, and your symptom pattern together.

You’re not imagining that something isn’t working. You’re also not out of options. You may just be at the part of the treatment journey where the specificity of care matters most.

Frequently Asked Questions

Are mood stabilizers addictive?

No. Mood stabilizers — including lithium, lamotrigine, valproate, and carbamazepine — do not cause physical dependence or produce the tolerance and withdrawal patterns associated with addictive substances. They can be discontinued, though doing so should always be done gradually and in consultation with your prescriber — not because of addiction risk, but because abrupt discontinuation significantly increases the risk of relapse.

Can I take mood stabilizers long-term?

Many people take mood stabilizers for years or decades. The APA notes that because bipolar disorder is a chronic illness in which mood episodes typically recur, ongoing preventive treatment is recommended. Long-term lithium and valproate use do require regular monitoring for renal, thyroid, and liver effects respectively — but with monitoring in place, long-term use is standard clinical practice.

Why does my prescriber use blood tests to adjust my dose?

For lithium, valproate, and carbamazepine, the therapeutic range — the blood level at which the medication is most effective with acceptable side effects — is relatively narrow. Below it, the medication may not provide sufficient protection; above it, side effects or toxicity become more likely. StatPearls confirms that monitoring before initiation and regularly thereafter is the standard of care. Blood levels give prescribers objective data to calibrate dosing to your specific physiology, not just a standard starting point.

Is lamotrigine safe for someone of reproductive age?

Compared to valproate and carbamazepine, lamotrigine carries a substantially lower teratogenic risk. A 2024 review found that lamotrigine is generally considered a safer option for reproductive-age patients, while noting that the increased risk of oral clefts (~0.4%) and the higher risk with polytherapy should be discussed with a prescriber if pregnancy is a possibility. Phenotype testing can also screen for genetic predispositions to serious lamotrigine hypersensitivity reactions.

What if I’ve tried multiple mood stabilizers and nothing has fully worked?

Treatment-resistant bipolar disorder is real, and it is not a reflection of how hard you’ve tried. More than 50% of people with bipolar disorder are non-adherent to treatment at any given time — and a significant portion of those cases involve medications that weren’t well-matched to begin with. If you’ve cycled through multiple medications without sustained relief, the relevant questions are: Were therapeutic serum levels actually achieved? Was the medication matched to your polarity pattern? Was combination therapy considered? These are the conversations that benefit from a bipolar-specialist prescriber rather than a generalist.

What This Means if You’re Questioning Your Current Regimen

The landscape of mood stabilizers for bipolar disorder is more differentiated than most people are told early in their treatment. Lithium and valproate are strong for mania; lamotrigine is the best-evidenced option for depression prevention; only lithium carries robust anti-suicide data; carbamazepine fills a niche for treatment-resistant or mixed presentations. CANMAT’s evidence hierarchy gives these distinctions clinical weight — it’s not just opinion.

If you’re already on medication and wondering whether it’s the right fit, the most useful thing you can do is bring that question into a clinical conversation with a prescriber who has deep bipolar expertise. Not because anything is necessarily wrong — but because the specificity of bipolar prescribing means there’s almost always more nuance available than a standard appointment covers.

The monitoring isn’t just overhead. The titration timeline isn’t just bureaucracy. And the difference between a medication that addresses your dominant pole and one that doesn’t can be measured in years of your life.

If you’re curious what medication management looks like with a bipolar-specialized prescriber, see what care at Sway Health looks like.